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     ABSTRACT 
BACKGROUND 
   Metabolic syndrome includes hypertension, obesity, 
insulin resistance and dyslipidemia. Metabolic syndrome helps in early 
identification of the people at risk of developing diabetes and cardiovascular 
diseases. The prevalence of metabolic syndrome varies from 50%-80% in 
various parts of the world. Thus early recognition of metabolic syndrome is 
needed.  
AIM 
1. To study the prevalence of metabolic syndrome in newly diagnosed 
hypertensive individuals. 
2. To study the prevalence and pattern of lipid profile abnormalities in 
hypertensive individuals. 
To study the clinical, demographic and social parameters  influence on lipid 
profile abnormalities. 
METHODS 
  In this cross sectional study, 150 newly detected hypertensive 
individuals were included in the study. All participants were explained about the 
study and informed consent was obtained. They were investigated for fasting 
blood glucose, lipid profile including total cholesterol, triglycerides, high 
density lipoprotein . Anthropometric measurements were made. Statistical 
analysis was made using SPSS 16 software . The difference between various 
parameters were considered statistically significant if the p value was <0.05. 
RESULTS 
  The study population of 150 newly detected hypertensive individuals, 
there are 78 (52%) males and 72 (48%) females. The mean age of the study 
population is 55.68 years. 
The prevalence of metabolic syndrome calculated according to NCEP ATP 
III criteria is 59.33% that is 89 patients out of 150 newly detected hypertensive 
people. There is no statistical difference in the prevalence of metabolic 
syndrome on the basis of gender, age. Statistical significant difference in the 
prevalence of metabolic syndrome among smokers compared to non-smokers. 
The people with sedentary lifestyle had significantly higher prevalence. The 
prevalence of metabolic syndrome was significantly higher in  people in stage 2 
hypertension. The prevalence of each component of metabolic syndrome in 
male is found to be elevated triglycerides (80.76%), abnormal waist 
circumference (46.15%) , low HDL (43.58%), impaired fasting blood glucose 
(26.92%) and in females the same component’s prevalence are 73.61%, 
72.22%, 12.5%, 15.27% respectively.The prevalence of each component in 
patients with metabolic syndrome in our study shows that in male, elevated 
TGL (97.67%)is the most common component being seen. It is followed by 
abnormal waist circumference (79.06%), low HDL (76.74%), impaired blood 
glucose (39.53%). Among females with metabolic syndrome the prevalence of 
components are low HDL (97.8%), elevated TGL (93.47%), abnormal waist 
circumference (89.13%), impaired blood glucose (17.39%).The prevalence of 
lipid profile abnormalities in hypertensive patients is elevated TC 43.33%, 
elevated TGL 76.8%, elevated LDL 28.66% and low HDL 44.4%. The 
prevalence of elevated total cholesterol was significantly higher in patients with 
age ≥50 years.The prevalence of low HDL among male and female is 43.58% 
and 12.5%. The difference between the two is statistically significant.The mean 
values of lipid profile abnormalities are compared between sedentary and non-
sedentary hypertensive people and it is significantly higher in sedentary 
group.There is significant difference in the lipid profile values of obese people 
compared to non-obese individuals. 
CONCLUSION 
  The prevalence of metabolic syndrome is high in newly detected 
hypertensive individuals. People with sedentary lifestyle, smokers, stage 2 
hypertensive people had significantly higher prevalence of metabolic 
syndrome. The dyslipidemia was seen significantly higher in people with age ≥ 
50 years, sedentary people and obese people. 
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Metabolic syndrome, hypertension, dyslipidemia, obesity 
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1METABOLIC SYNDROME   IN   NEWLY   DETECTED   HYPERTENSIVE
INDIVIDUALS
INTRODUCTION
Metabolic syndrome is the term given to address a collection of risk factors. These
risk factors are considered to increase risk for diabetes mellitus, coronary artery disease
and cerebrovascular accident1. These diseases in turn lead to adverse outcomes causing
1.6 times increase in mortality. In 1975 the term “metabolic syndrome” was given by
Haller and Hanefeld2. Various terms used to denote metabolic syndrome are
‘dysmetabolic syndrome’, ‘hypertriglyceridemic waist’, ‘insulin resistance syndrome’,
‘obesity syndrome’ and ‘syndrome X’. Obesity and resistance to insulin are found to be
mainly caused by absence of physical work, sedentary lifestyle and poor dietary habits like
fatty foods.
Metabolic syndrome includes resistance to insulin, elevated blood pressure,
elevated lipid profile and obesity. All components of metabolic syndrome are mostly
preceded by obesity. Atleast 3 out of five components is necessary to make a diagnosis of
metabolic syndrome. Ethnic and national specificity is required for waist circumference.
Genetics, ageing, state of inflammation and changes in hormone may also have a
causal effect, but the role of these may vary depending on ethnic group. Certain risk
factors that are non-classic like c-reactive protein, abnormal oxidized low-density
lipoprotein-cholesterol and adiponectin are very much related to metabolic syndrome.
2From a practical clinical perspective and also from a clinical standpoint people at
high metabolic risk are identified by using the metabolic syndrome criteria. A high level of
low-density lipoprotein-cholesterol which is a traditional risk factor may be absent and so
the individuals at high risk might be overlooked if these metabolic syndrome criteria are
not utilized.
As metabolic syndrome being the important factor leading to two major diseases,
cardiovascular diseases and type 2 diabetes, there is an immense need on social, moral and
on medical perspective for early detection of people with metabolic syndrome. Thus the
onset of diseases like diabetes , cardiovascular disease can be prevented very well by
identifying metabolic syndrome earlier . These people can be advised and subjected to
lifestyle modifications and started on appropriate treatment .
Thus metabolic syndrome is helpful in rapid identification of people at high
metabolic risk. This study is conducted to find the prevalence of metabolic syndrome in
newly diagnosed hypertensive individuals and the factors influencing lipid profile
abnormalities in hypertensive individuals.
3AIM OF STUDY
1. To study the prevalence of metabolic syndrome in newly diagnosed hypertensive
individuals.
2. To study the prevalence and pattern of lipid profile abnormalities in hypertensive
individuals.
3. To study the clinical, demographic and social parameters influence on lipid profile
abnormalities.
4REVIEW OF LITERATURE
METABOLIC SYNDROME
Metabolic syndrome is associated with an imbalance between energy intake
and energy storing capacity. This imbalance results in ectopic lipid deposition in
visceral fat, skeletal muscle (insulin resistance), liver (non-alcoholic steatohepatitis),
pancreatic beta cells and vessel wall or macrophages (coronary artery disease)3. The
metabolic syndrome may occur in obese and non-obese people.
Lipid storage occurs in visceral reservoirs, in the people who lack
subcutaneous fat as in non-obese patients. Spillage of lipids to muscle, blood vessels,
pancreas and liver occurs after the filling of these reservoirs. Staging of chronic
diseases are set based on this. Metabolic syndrome acts as a predictor of the chance of
developing type 2 diabetes and cardiovascular disease in case of presence of visceral
obesity.
The people with metabolic syndrome, who are not obese are also expected
to face the risk of cardiovascular disease and other associations of metabolic
syndrome because of the fat being deposited in the viscera. Certain factors being
secreted by the visceral fat known as ‘adipocytokines’ are responsible for the
development of metabolic syndrome. they are resistin, (TNF) tumour necrosis
factor, (IL) interleukins and leptin.
5GENETICS OF METABOLIC SYNDROME
There  is  difficulty  in  identifying  the  genetic  component  of metabolic
syndrome because of few factors. They are varying lifestyle factors, absence of a
single defining criterion for metabolic syndrome, complexity of metabolic syndrome4.
From linkage analysis, genome wide association studies and candidate gene approach,
metabolic syndrome having a genetic component has been identified.
FAMILY AND TWIN STUDIES
Regarding genetics of metabolic syndrome , further more details have been
provided by numerous family and twin studies. As per NCEP:ATPIII criteria, the
heritability every single component, was found out. It was 20% for elevated blood
pressure, 16-60% with dyslipidemia/hyperglycemia and 44% with obesity5. The
metabolic syndrome as such from studies conducted among 89 Caribbean-Hispanic
families showed a heritability of 24% (p = 0.006) in 203 subjects. Italian individuals
of 293 were subjected to a similar study. The heritability of metabolic syndrome was
found to be 27% (p = 0.002) as per NCEP ATP III criteria. 54% and 10% was the
heritability of low high-density lipoprotein and elevated blood glucose. The maximum
heritability was found to be 31% (p <0.001) for high low density cholesterol (LDL),
central obesity and elevated blood pressure6.
LINKAGE STUDIES
Many studies have been conducted on different combination of components
6and on individual components of metabolic syndrome than on metabolic syndrome as
such since it is a complex disorder. Numerous studies have been conducted to find the
genes that are associated with the development of metabolic syndrome. It is done by
using linkage studies. This led to the discovery of a quantitative trait loci (QTL). It
was found to be present in the chromosome 3 on studying 507 families from U.S7.
Another study conducted showed that there is an association between the
chromosomes 10, 19 and blood sugar, blood pressure, low high density lipoprotein,
triglyceride , increased body and viscera fat. Association was also found with
chromosome 18.the association between the chromosome and the genes varied
between different ethnic groups9.
GENOME-WIDE ASSOCIATION STUDIES
Further many studies were conducted to on genome wide association studies
and its relation to metabolic syndrome. Type 2 diabetes and its relation to the gene
known as (FTO) obesity associated protein gene was found by single nucleotide
polymorphism by the International Association for the study of obesity (IASO). From
the study evidences were found that there is a relation between the gene and the
development of diabetes. It was seen that the people who had the homozygous status
for the gene were heavy and had increased risk of becoming obese10. Thus a linkage
between these genes that is FTO and others was found to be present with obesity by
its effects on body mass index. This association was seen in European11-15 as well as
7Asian people16. But still more studies and researches are need to confirm this relation
between the gene and body mass index.
The components of metabolic syndrome have been found to related many
single nucleotide polymorphism as per many studies. These genes are found to be
associated with central adiposity, resistance to insulin and metabolism of lipids. Yet
may studies are needed to establish this linkage to metabolic syndrome.
REASON BEHIND THE OCCURRENCE OF COMPONENTS TOGETHER
Metabolic syndrome development is induced by interaction of factors that
occurs together. Increased weight, especially central obesity leads to all other
components to arise. The factors that occurs mostly together are high blood pressure,
abnormal lipid profile, high blood sugar level. Central obesity is considered as an
important factor leading to high values of blood glucose by causing resistance to
insulin, abnormal lipid profile, high blood pressure and high blood sugar levels17.
8Figure 1
9The cause for occurrence of these factors together was studied by Meigs et
al17. The concept behind happening of all components altogether in individuals
leading to metabolic syndrome was studied as a cohort study. Factor analysis proved
that 3 things that reason out the grouping together of various components. The first
thing is the one which leads to the onset of resistance to insulin. This comprises of
lipid profile abnormalities, central obesity. The next thing is the one that causes blood
sugar impairment and development of diabetes by causing the loss of function of
pancreas. The last one is responsible for causing elevation in blood pressure. Thus the
presence of all components altogether in metabolic syndrome is influenced by many
factors that act individually. These components are mostly normal physiological
factors but they lead to the occurrence of metabolic syndrome17.
The pathogenesis for diabetes occurrence was studied in 1087 people who are
not diabetics. The study was done by Hanley et al18. The analysis was done to know
whether the elevated blood sugar is caused not only by metabolic causes but also by
many inflammatory factors. It known as ‘Insulin Resistance Atherosclerosis Study’.
The things that were analyzed are sensitivity to insulin and factors that causes
inflammation.
The study results found that there are 3 things that are important,
1) “metabolic” – sensitivity to insulin, central obesity like abnormal body mass
index, plasminogen activator factor, high values of blood glucose.
10
2) “inflammation” – sensitivity to insulin, circumference of waist, fibrinogen, body
mass index
3) “blood pressure” – the prediction of development of diabetes was studied after a
following for few years.18
Risk of incident diabetes
Univariate models OR 95% CI
from to
Metabolic factor 2.26 1.82 2.80
Inflammation factor 1.57 1.32 1.87
Blood pressure
factor 1.44 1.20 1.73
TABLE 1- The predictor of later occurrence of diabetes is metabolic syndrome.
p = 0.0001
The factors that lead to cardiovascular diseases in people who are not known
diabetics are studied18. The studies proved that these factors are responsible for
grouping together of various components of metabolic syndrome. They are sensitivity
to insulin, central obesity factors like body mass index, circumference of waist. They
were several metabolic factors and also things that cause inflammation.
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OBESITY
According to many studies there is a drastic increase in people who are obese,
and it is seen all over the world. Obesity refers to the accumulation of fat in the body
that occurs beyond normal. It is measured by many parameters like measuring the
circumference of waist or calculating the body mass index. Now we have come to
know that among the components of metabolic syndrome obesity is important one and
for establishing a diagnosis of metabolic syndrome19.
It was estimated that the people who are obese increases rapidly and a study by
Finucane et al21 there were more than one billion obese people with a body mass
index of above 25kg/m 2 . And this comprises of people who are obese and also who
are overweight. This population has been reached from a one billion population of
obese people from 2005.thus it was also concluded that this would lead to a obese
population of more than 1.5 billion by 2015.20
The people who are obese or abnormal body mass index in America was found
to be around 150 million of adults. This is as reported by the American heart
association22. Thus the facts of increasing number of people with obesity shows that
metabolic syndrome is a factor that has to be given prime importance to prevent the on
12
Figure 2. The above figure depicts the role of all components of metabolic syndrome.
Central adiposity is the main component that leads to the arise of other components
like elevated blood pressure, abnormal lipid profile, resistance to insulin, all these are
found to be the components of metabolic syndrome. The figure shows that obesity and
excess of weight is caused by increased consumption of food containing fat and
inactive sedentary lifestyle. Excess fat intake leads to abnormal lipid profile and
resistance to insulin. High blood pressure, increase in lipid profile values, resistance to
insulin are caused by central adiposity.
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INSULIN RESISTANCE
Syndrome X is term used to describe the occurring together of factors of
metabolic syndrome. It is coined by Reaven at 1988. By 2030 it is estimated that
around 300 million people in the world would develop diabetes .Though obesity is the
important factor, it has been found that several genetic and environmental factors
leads to the diabetes development and resistance to insulin23. In 2000 , it was found
that around 200 million were having diabetes24 and around 40% of the population was
found to have insulin resistance25. Like obesity, insulin resistance is also an important
factor leading to cardiovascular diseases. Pancreatic beta cell dysfunction is caused by
high level of fatty acids24. High blood pressure, increased weight, high blood sugar,
lipid profile abnormalities are found be caused by the factor insulin resistance25.
DYSLIPIDEMIA
Dyslipidemia is considered to be another important component of metabolic
syndrome along with the other factors like central adiposity and resistance to insulin.
It includes many parts like elevated low-density lipoprotein (LDL), elevated
triglycerides (TGL), fatty acids (FA), apolipoprotein (apo B)27. Albrink studied the
link between the components like high blood pressure, elevated triglycerides,
abnormal weight. Later many studies were conducted by him to study the relation
between metabolic syndrome and lipid profile abnormalities26. The association
14
between atherosclerosis and resistance to insulin was established by Insulin Resistance
Atherosclerosis Study after many years. It was found that the fatty acids not only plays
a crucial role in causing resistance to insulin in people who are not obese but also it
leads to elevation in the level of TGL causing hypertriglyceridemia26.
Abnormal production of apo B, increased production of very low density
lipoprotein, reduced metabolism of apo B and accelerated breakdown of HDL are
factors causing dyslipidemia in people with metabolic syndrome. In metabolic
syndrome patients, dyslipidemia may be caused by a combination of the
overproduction of very-low-density lipoprotein, over-production of ApoB, decreased
breakdown of ApoB and increased catabolism of HDL cholesterol. These changes are
attributed to insulin resistance. All of these may be a consequence of IR 27. Thus the
most significantly seen components of dyslipidemia in patients with metabolic
syndrome are elevated levels of low density lipoprotein, low HDL, high fasting and
postprandial TGL29. (Fig. 3).
15
Figure 3 The occurrence of dyslipidemia from the state of resistance to insulin and
obesity . Raised FA leads to increase in level of VLDL which inturn raises the TGL
levels and thus it increases the levels of small dense LDL and low level of HDL.
HYPERTENSION
Studies conducted at many sites have shown that approximately 85% of people
with metabolic syndrome have high level of blood pressure that is hypertension as the
main driving factor for other components30. Most of the time the diagnosis of
hypertension is not made early. This leads to the development of serious conditions
like renal failure and heart diseases31. Almost 50% of people with elevated
16
blood pressure are found to be resistant to insulin26. Obesity and resistance to insulin is
found to be the important cause for the high blood pressure31. The altered response to
insulin is seen in people with insulin resistance. Normally, vasodilation occurs on
introduction of insulin inside the blood stream due to the release of nitric oxide. But in
people with insulin resistance, this response is not seen26 and rather there occurs
activation of renin angiotensin aldosterone system by the state of hyperinsulinemia, that
causes high blood pressure and constriction of blood vessels30.
A study conducted in U.S. showed that the frequency of high blood pressure is
more high than other components in males with metabolic syndrome (41%) whereas in
female the frequency was in the following order, Abnormal waist circumference in 52%,
Low high density lipoprotein in 43% and then high blood pressure in 37%. It was
conducted in adults of age above twenty years in 1999-2000 by NHANES32.
METABOLIC SYNDROME
There are criteria for defining metabolic syndrome. They are modified NCEP-
ATP III and IDF criteria.
INTERNATIONAL DIABETES FEDERATION CRITERIA
People were said to have metabolic syndrome according to IDF criteria, if the
patient had central obesity that is abnormal waist circumference that is more than or
17
equal to 94 cm in male and more than or equal to 80 cm in female- along with other any
2 factors
(1) high TGL (≥150 mg/dl);
(2) low HDLC (<40 mg/dl in males and <50 mg/dl in females);
(3) high blood pressure (systolic BP ≥130 or diastolic BP ≥85 mmHg) or on drugs for
hypertension;
(4) elevated fasting blood glucose (≥100 mg/dl)
MODIFIED NCEP-ATP III DEFINITION
When three or more of the components were present the person is said to have
metabolic syndrome.
(1) central obesity (waist circumference >90 cm in males and >80 cm in
females Asian-Indian criteria);
(2) high TGL (TG ≥150 mg/dl);
(3) low HDLc (<40 mg/dl in males and <50 mg/dl in females);
(4) elevated BP (≥130/85 mmHg);
(5) impaired fasting blood glucose (≥100 mg/dl)
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METABOLIC SYNDROME AND ITS EFFECTS
Studies have enough evidence to say that people with metabolic syndrome are
having increased risk of developing cardiovascular diseases and diabetes. The risk is 3
fold for heart diseases and 5 fold for developing diabetes. Though there are evidences to
take it as risk factor , the relative risk for each person cannot be individualized so far for
the heart diseases and diabetes33.
HEART DISEASES
The  cardiovascular  diseases  have  become  the  leading cause of death in the
developed countries as well as in the developing countries. So as early diagnosis of
metabolic syndrome is warranted , since atleast the risk of developing cardiovascular
diseases in future could be known34. The metabolic syndrome not only as a whole
increases a person’s risk to develop heart diseases but every single factor of metabolic
syndrome is found to have an effect and act as a risk factor 35.
The metabolic syndrome’s prevalence was studied in 2493 people, by using two
criteria. It was found that according to NCEP ATP III criteria the prevalence was 16%
and according to IDF criteria it was 21%. The study mainly analyzed the association
between resistance to insulin, heart disease and metabolic syndrome. Follow up was done
for a period of around 10 years, then it was found that 233 participants of the study died
19
from heart diseases leading to coronary artery diseases, stroke. The cardiovascular
disease’s incidence was studied and it was 16.6% as per NCEP ATP III definition and
14.6% as per IDF definition. Thus it was concluded that NCEP ATP III is better criteria
with respect to predicting the cardiovascular disease than IDF criteria. Resistance to
insulin acts as a risk factor to heart disease both as an individual factor as well as in
combination with metabolic syndrome36. The predicting power of NCEP ATP III was
found to be more in terms of cardiovascular diseases.
DIABETES MELLITUS
Diabetes mellitus is also a mixture of many metabolic conditions like abnormal
lipid profile, overweight , elevated blood glucose and resistance to insulin similar to that
if metabolic syndroeme38. The onset of diabetes is preceded by the factors like elevated
lipid profile, resistance to insulin, high levels of insulin and abnormal weight in almost
85% of people. This condition is seen in almost 150 million people and might double by
202037.
Along with insulin the role of the hormone glucagon is being studied. It shows that
the pancreatic beta cell failure is first preceded by dysfunction of alpha cells of the
pancreas seen in case of people with diabetes mellitus39. The dysfunction of alpha cell is
seen both in type 1 and type 2 diabetes. This loss of function leads either more secretion
or reduction in the suppression of alpha cells in the diabetic patients. It was found that the
20
level of glucagon is high in people with diabetes leading to increased blood glucose and
dysregulation of glucose metabolism40. Further studies have showed glucagon like
peptide-1 (GLP-1) is also increased in these diabetic patients. Glucagon like peptide-1
causing glucagon and insulin regulation is an integrin that is being secreted in intestine.
The level of glucagon like peptide-1 in people was studied in people with and without
metabolic syndrome. it was found that the levels were higher in people with metabolic
syndrome. The difference was statistically significant. It also had relation to every single
factor of metabolic syndrome. These patients are more prone to develop heart diseases41.
CANCER
There are studies which show that there exists a relation between the metabolic
syndrome and the incidence of cancer. But there is no clear evidence to substantiate it.
The cancer prevalence is found to increase worldwide. Almost 20% of the cancer death
are attributed to obesity42 .
RELATION BETWEEN CANCER AND OBESITY
Studies conducted so far has shown that association lies between the obesity and
malignancies. Though the mechanism is not known clearly, the association is seen
between malignancies of pancreas , kidney, ovary, breast , endometrium and
esophagus43,44. Resistance to insulin that is seen in obese individuals leads to oxidative
21
stress and also increases the insulin like growth factor-144. This is a possible mechanism
that has been suggested for the occurrence of malignancies.
ASSOCIATION WITH INSULIN RESISTANCE
The mechanism for the development of malignancy in patient with insulin
resistance has been studied. The increase in levels of insulin in the blood due to
resistance leads to increase in blood glucose levels and increase in synthesis of glucose.
The insulin also induces mitosis which inturn is affected by the reactive oxygen species
that is produced in excess in people with high levels of blood glucose and high levels of
fatty acids. Mutation occurs in the (DNA) deoxyribonucleic acid and leads to
development of cancer. The high levels of insulin leads to reduction in sex hormone
binding globulin and increase in insulin like growth factor. All the changes leads to
carcinogenesis. These factors also leads to sex steroid secretion from the ovaries that
leads to cancer in endometrium and breast46.
MALIGNANCY AND LIPID ABNORMALITY
The low high density lipoprotein and high levels of low density lipoprotein is
associated with increase in the odds of developing cancer. Studies have shown that
around 2.3% drop in the chances of malignancy development if the level of high density
lipoprotein increases by one mg/dl. The malignancy that could occur are gastrointestinal,
prostrate and breast malignancies47.
22
HYPERTENSION
PATHOPHYSIOLOGY OF HYPERTENSION
ENVIRONMENTAL AND PSYCOSOCIAL STRESS
Increase in blood pressure was observed in over the lifespan of people who settled
in stressful urban region from traditional, calm rural environment48. Westernized  people
with low socio economic status have higher BP49. Type A  or Coronary  prone  behavior
pattern  is linked with hypertension and risk of  cardiovascular disease50. Anger  arousing
experiments have long been known to  raise  BP and increase vasoconstriction51,52.
Other psychological factors related to increase in BP are power motivation (desire to
dominate others), depression53,54, hopelessness and  pessimism . The effect of persistent
hopelessness was equivalent to that  of smoking 2.5 packs of cigarettes daily 55,56 .  The
stress buffers like social support, aerobic exercises and stress reduction interventions like
bio feedback , relaxation training and cognitive behavioral therapies have been shown to
lower B.P. with mixed success 57.
RENIN-ANGIOTENSIN SYSTEM (RAS)
In humans, rennin is coded for by a single gene in chromosome-1. It is secreted by
juxta- glomerular cells in response to decrease perfusion. The rennin converts
angiotensinogen to angiotensin I which is converted to angiotensin II by ACE.
23
Angiotensin II is thought to be responsible for most of the physiologic and
pathophysiologic effects of RAS. Evidences are accumulating that ACE polymorphism
due to insertion or deletion may be responsible at least a part to the pathology of essential
hypertension58-60.
ALDOSTERONE AND MINERALOCORTICOIDS.
Apart from the physiological role in retaining Na + and excreting K + in epithelial
cell, Aldosterone has other less explored functions like vasoconstriction by acting on
vascular smooth muscle, in brain to stimulate salt appetite and direct action on cardiac
myocytes which may contribute to essential hypertension.
INSULIN RESISTANCE AND HYPERINSULINEMIA.
Though the relation between hyperinsulinemia and hypertension is well
established the mechanisms by which it rises the BP remains doubtful and complex. The
possible mechanisms include.
1. Insulin mediated salt retention 61,62.
2. Insulin activation of sympathetic nervous system 63,64.
3. Proliferative effects of insulin65.
4. Non enzymatic glycation of interstitial tissues in arterial walls 66.
5. Insulin induced endothelial dysfunction leading to arterial stiffness.
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REMODELLING OF RESISTANT ARTERIES IN HYPERTENSION.
Abnormalities of endothelial cells, smooth muscle cells, adhesion molecules and
extra cellular matrix in vasculature may contribute to structural, mechanical and
functional changes that reduce lumen diameter of small arteries (400 – 100 micron).There
are two types of remodeling.
1. Eutrophic remodeling in which the cross sectional area of lumen is maintained
2. Hypertrophic remodeling in which the cross sectional area of lumen is increased.
Of these the Eutrophic remodeling occurs in essential hypertension.
ENDOTHELIUM IN HYPERTENSION
The two major endothelium derived vasoactive substances are Nitric oxide (NO)
and Endothelin (ET).Nitric oxide is released from endothelium in response to shear stress
and exerts vasodilating and antiproliferative effects on smooth muscle cells. It also
inhibits the thrombocyte aggregation and leucocyte adhesion. The whole body Nitric
oxide production in patients with essential hypertension is diminished under basal
conditions67,68. Oxidative stress plays an important role in the pathogenesis of
hypertension by oxidation of Nitric oxide to peroxynimine by superoxide anion thereby
effectively reducing the bioavailability of Nitric oxide 69,70.
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Endothelin exerts its major vascular effects, vasoconstriction and cell proliferation
through ET A receptors on vascular smooth muscle cells. In contrast ET B receptor
mediate vasodilation via release of NO and prostacyclin. Apart from the effects on blood
vessels it also causes sodium retention and Renin release in kidneys , Aldosterone release
from adrenals and hypertrophy and fibrosis of heart musculature.These effects may
contribute to essential hypertension in human71-73.
NATRIURETIC AND VASODILATORY PEPTIDES
The natriuretic peptides including ANP , BNP , CNP , DNP and urodilantin
performs multiple functions like natriuresis, vasodilation , anti- proliferative effects ,
vascular remodeling and modulation of nor adrenergic and RAAS . In addition to these,
the vasodilatory peptides like calcitonin gene related peptide (CGRP), substance P and
Adrenomedullin regulates cardiovascular function in normal state and in hypertension.
THE KALLIKREIN – KININ SYSTEM
The kininogenic enzymes act on kininogen to form kinins. The kinins act via two
receptors . The B1 receptor mediates inflammation , pain and fibrosis, the B2 receptor
mediates the depressor , natriuretic , antitrophic and fibrinolytic functions via mediators
like Eicasanoids , EDHF ( endothelium derived hyperpolarizing factors ) , NO, t-PA etc.
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CONCEPT OF VASCULAR STIFFENING
A  decreased  distensibility  of aorta and other large arteries or the loss of  the
windkessel  function is known to be a cause for hypertension. This vascular Stiffening
develops from complex interaction   between  structural and celluar elements  of vessel
wall . The  structural   components   include   2 prominent scaffolding proteins , collagen
and elastin . Dysregulation of the balance between the  production  and degradation of
collagen and decreased  production of elastin which contribute to vascular stiffness 74.
These vascular alterations  are influenced by intrinsic   factors 75 like hemodynamic
forces   and extrinsic factors like hormones, salt, glucose and lipids 76. In addition  to the
structural components , cellular components also play a role in the  pathogenesis of
vascular  stiffening .  They  are signals  from endothelial cells like  NO and Endothelin -1
and the vascular smooth muscle tone. The Vascular  smooth  muscle   tone  is  modified
by mechanostimulation and by paracrine mediators like Angiotensin II , ET -1 , oxidative
stress and nitric oxide77 .
DEFININIG HYPERTENSION
The multiple risk factor intervention trial (MRFIT ) demonstrated a continuous
and graded influence of both systolic and diastolic blood pressure of coronary heart
disease mortality extending down to systolic blood pressures of 120 mm Hg. No definite
level of blood pressure is there to define blood pressure.
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Clinically “Hypertension  may be defined as that level of  Blood  pressure at
which the institution of therapy reduces Blood pressure related morbidity  and
mortality”.  The  JNC VII classifies hypertension as follows
SBP (mm Hg ) DBP ( mm Hg)
Normal <120 And <80
Pre HT 120-139 Or 80-89
Stage 1 140-159 Or 90-99
Stage 2 >/ 160 Or >/100
ISH >/140 And <90
TYPES OF HYPERTENSION
Based on the evaluation of patients, 80-95% of people with high blood pressure
are said to have “Essential Hypertension ( also called as Primary or Idiopathic
Hypertension ) . In the remaining 5-20 % , a specific underlying disorder causing the
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elevation of blood pressure can be identified. These group is called “ SECONDARY
HYPERTENSION”.Essential Hypertension tends to be familial and is likely to be the
consequences of an interaction between environmental and genetic factors.
PATHOLOGIC CONSEQUENCES OF HYPERTENSION
Hypertension is a risk factor for atherosclerosis . It is an independent
predisposing factor for heart failure,coronary artery disease, stroke, renal disease and
peripheral arterial disease.
HEART
Hypertensive   heart   disease  is the result of structural and functional adaptations
of heart leading to left ventricular hypertrophy, diastoloic dysfunction, congestive heart
failure, coronary heart disease, microvascular disease and cardiac arrythmias.
BRAIN
Hypertension is an important risk factor for brain infarction and haemorrhage .
Hypertension is also associated with an impaired cognition in aging population . In
malignant hypertension there is loss of cerebral auto regulation leading to hyperperfusion
causing encephalopathy .
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KIDNEY
Hypertension is an important risk factor for renal injury and ESRD. The
atherosclerotic  hypertension  related vascular  lesion  in kidney primary affect the pre
glomerular arterioles , resulting in  ischemic changes in glomeruli and post glomerular
structures  . The injury may also be  due to  direct damage to the glomerular capillaries
due to   hyperperfusion  . The pathology   progress   to glomerulosclerosis  and eventually
to gradual atrophy of tubules. The renal lesion  associated  with  malignant hypertension
consists of fibrinoid necrosis of afferent arterioles and sometimes the necrosis of
glomerular tuft.
ARTERIAL DAMAGE
Hypertension is caused by changes in the blood vessels and the high blood
pressure inturn leads to damage to the blood vessels. These damages leads to retinopathy,
intermittent claudication.
PATIENT APPROACH & EVALUATION
Once the patient comes first the causes of hypertension are analyzed and the
secondary causes of hypertension need to be screened. Then the factors that might lead to
heart diseases to be screened. Most of   the   hypertensive patients  have  no  specific
symptoms referable  to  elevated BP . Only people with severe hypertension are known to
have headache. Headache generally occurs only in patients with severe hypertension .
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Patients mostly complain of morning, occipital headache. Dizziness, easy fatigability,
palpitation and impotence may also be the presenting complaints of the patients.
MEASUREMENT OF BP
The person for whom the blood pressure is measured is made to sit in a room at
comfortable room temperature as well as in a calm setting. The blood pressure measuring
cuff has to be atleast 40% of the arm circumference . The arm in which the cuff is tied is
to be placed at the level of heart. After inflating the cuff, it has to be deflated at a rate of
2mm of mercury/ second. Korotkoff sounds are used to measure the blood pressure. The
tapping sound of the korotkoff sounds is taken as the systolic blood pressure . The point
when the regular korotkoff sound is heard for last time is taken as the diastolic pressure.
Nowadays the oscillometric method is used for measuring the blood pressure.
They measure the blood pressure every fifteen to thirty minutes. They are automated
ambulatory machines. As per recommendations of JNC VII , the usage of ambulatory
blood pressure monitoring for people with episodic hypertension, resistant hypertension
and symptomatic hypertension. Thus ambulatory measurement is not used for all patients.
EXAMINATION OF THE PATIENT
Anthropometric measurements are made , that is height and weight of the patient
is measured. The bloodpressure measurement is done in both right and left arm with the
patient in sitting posture and also in standing and lying down in supine position. In
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hypertension diagnosed before the age of 30 years, lower limb BP should be checked. All
the peripheral pulses should be examined for rate, rhythm , volume and character. Heart
rate should be recorded . Examination of the neck is done for thyroid gland . Fundus is
also examined for signs of retinopathy. Auscultation is done for bruit over
carotids,femorals and renal arteries is done. Cardiac auscultation for loud S2 and S4
Gallop is done. Palpation of the precordium is done for a heaving apical impulse.
LABORATORY TESTING
Basic laboratory testing for initial evaluation
RENAL ELECTROLYTES METABOLIC OTHERS
Urine microscopy Serum sodium FBS Hematocrit
Urine albumin Serum potassium Lipid profile ECG
BUN Serum calcium
Serum creatinine
The aim of   anti - hypertensive management by various means is to bring down
and to maintain the BP below 140/90 mmHg. In diabetic patients the BP goal is 130/80
mmHg and in nephropathy patients it is125/75 mmHg.
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DYSLIPIDEMIA
Dyslipidemia is the most prevalent and important modifiable risk factor for
atherosclerosis . Proper treatment reduces the risk for cardiac death, non fatal MI, stroke,
and peripheral vascular disease by 25 – 50 %. Despite these benefits only 20 % of adults
meet national guidelines for cholesterol control.
Dyslipidemia is defined as abnormal lipid status. Common lipid abnormalities
include elevated total cholesterol, LDL cholesterol, lipoprotein ( a) and triglycerides ,
low level of HDL cholesterol and a preponderance of small density LDL particles. These
abnormalities occur alone or in combination.
PREVALANCE, RISK AND SCREENING
Approximately 50%  of US  adults have an elevated  total cholesterol. In a vast majority
of the patients with atherosclerotic vascular disease there is some form of   dyslipidemia
even  though  their total  cholesterol  is  normal.  Elevated  total cholesterol ,   LDL c  and
low HDL c levels are major modifiable risk factors for coronary heart disease and other
forms of  atherosclerotic vascular disease. ATP III recommends a  routine  lipoprotein
analysis for all adults aged 20 years. Screening should   be   repeated   every  5 years.
Since  dyslipidemia is an  asymptomatic condition, early recognition and treatment
improves prognosis.
33
EFFECT OF THERAPY
Several  large  randomized , placebo controlled trials of statin therapy have shown
reduction in cardio vascular morbidity  and mortality. A meta-analysis of more  than  330
interventional trials has  shown  that   for every   1 %  total cholesterol, mortality is
reduced by 1.5 % and for each 1 % reduction in LDL c and for each 1 % increase in HDL
c, the risk for cardiovascular events is reduced by 2 % and 3 % respectively 78.A number
of studies with serial angiography also show that the increase in stenosis was 1-3 % less
per year in aggressively treated patients than in placebo. The lower level of LDL c
maximum benefit extends to as low as 50 -70 mg/dl for high risk patients.
LDL  CHOLESTEROL GOALS
The LDLc goals are  individualized depending on their CHD  risk
MAJOR RISK FACTORS THAT MODIFY LDL GOALS 79
The first step in estimating the LDL c goal is counting the number of risk factors
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Cigarette smoking Age (male > 45 yrs ; women > 55 yrs)
Hypertension Obesity ( BMI > 30 kg/m2 )
Diabetes mellitus Physical inactivity
HDLc <40 mg/dl Atherogenic diet
Cardiovascular disease in family Emerging risks
with early onset
The next step in calculation of the 10 year risk of coronary heart disease using
the Framingham heart study risk score. Based on these, individuals are classified in 5
groups and their LDL c goals are set.
VERY HIGH RISK GROUP
• LDL c goal < 70 mg % 80
• 10 year risk for major coronary event
• 20 % Established CHD
• CHD equivalents
• Diabetes mellitus
• Multiple cardiovascular risk factors
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HIGH RISK
• LDL c goal < 100 mg % ,
• optional goal < 70 mg %
• Coronary heart disease
• Coronary heart disease risk equivalents
• 10 year risk > 20 %
> 2 risk factors
MODERATELY HIGH RISK
• LDLc goal < 130mg%,
• optional< 100 mg %
• 10 year risk 10- 20 %
> 2 risk factors
MODERATE RISK
• LDL c goal < 130 mg %
• 10 year risk < 10 %
> 2 risk factors
LOWER RISK
• LDL c goal < 160 mg %
0-1 risk factors
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NON HDL CHOLESTEROL 81
Non – HDL c is calculated by subtracting HDL c from TC.The primary goal of
therapy for persons with dyslipidemia is LDL-c lowering . A secondary goal of non -
HDL c is set by ATP III guidelines.
High / Very high risk - < 130 mg/dl.(optional < 100 mg / dl )
Moderately high risk - < 160 mg/dl.(optional < 130 mg / dl )
Moderate risk - < 160 mg / dl
Low risk - < 190 mg / dl
TREATMENT OF DYSLIPIDEMIA
THEREPEUTIC LIFE STYLE CHANGE 82-84.
This includes Diet, physical activity, weight reduction and smoking cessation . In
many individuals this could reduce total cholesterol by < 10%.
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DRUGS
DRUGS MECHANISM LIPID LOWERING
Statins HMG CoA reductase inhibitors
LDL c : 18 – 55 %
HDL c : 5 – 15 %
TG : 7 – 30 %
Ezetimibe Decrease cholesterol absorption
LDL c : 18 – 20 %
HDL c : 1 – 5 %
TG : 5 – 11 %
Niacin
Decrease production and release
of VLDL
LDL c : 5 – 25 %
HDL c : 15 – 35 %
TG : 20 – 50 %
Bile acid
sequesterants
Prevents enterohepatic circulation
of BA
LDL c : 15 – 30 %
HDL c : 3 – 5 %
TG : unaffected
Fibrates Increase LPL activity
LDL c : 5 – 20 %
HDL c : 10 – 35 %
TG
: 20 – 50 %
Omega 3
fatty acids
DHA and EPA reduce
VLDL production
LDL c : 44 % incr
HDL c : 9 %
TG : 45 %
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HIGH BLOOD PRESSURE AND ABNORMAL LIPID PROFILE -
The various factors of metabolic syndrome have found to be interlinked that is one
factor leads to the other and have a crucial role in other diseases onset. Similarly, the
abnormal lipid profile is also related to the development of increase in blood pressure in
many patients. So studies are conducted not only to study their relation but also to know
the effects of abnormal lipid profile on blood pressure. The effect of lipid lowering agents
on blood pressure is also being studied.
ROLE OF LIPIDS IN THE PATHOGENESIS OF HYPERTENSION
The mechanism by which the lipid profile abnormalities could lead to
increase in blood pressure is being studied. This shows that the endothelial lining of the
blood vessels are damaged by the lipid abnormalities and increase in blood pressure is
also caused by the dysfunction in the vasomotor activity. This endothelial dysfunction is
mainly caused by the atherogenic lipid profile abnormalities85. Endothelial damage
causes impairment in the expression of endothelin-1 and endothelin A&B receptor
expression86. The vasodilatory effect of nitric oxide and its production is also impaired.
These changes leads in increase in the blood pressure.
The relation between hypertension and dyslipidemia is studied and shows that
there is more increased expression of angiotensin-I. This is established by Nickenig and
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Harrison87,88 . And also over activity of sympathetic system is seen patients with
resistance to insulin and lipid profile abnormalities89.
CLINICAL TRIALS IN PATIENTS WITH HT & DYSLIPIDEMIA
ASCOT-LLA TRIAL90
(Anglo –Scandinavian cardiac outcome Trial-Lipid lowering arm)
In the above study there were two groups, one who received atorvastatin 10mg and other
who received placebo.10,305 men and women aged 40-79 years with high blood pressure
and with more than or equal to three risk factors were distributed randomly in the two
groups. Non fatal myocardial infarction, cardiovascular diseases, death are taken as the
primary end point of the study.
The Atorvastatin arm of the trial was stopped prematurely at 3.3 years due to a
significant 36% reduction in the primary end point. Benefits were apparent in the first
year . Atorvastatin also reduced fatal or non fatal stroke by 27%, total cardiovascular
events by 21% and total  coronary events by 29 % . At 1 year Atorvastatin reduced total
and LDL cholesterol by 24% and 35% respectively.
ALLHAT – LLT 91
(Anti hypertensive and lipid lowering treatment to prevent heart attack trial)
10,355 men and women aged >55 years with stage 1 and 2 hypertension , > 2 additional
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coronary heart disease risk factor and LDL c 120 -189 mg/dl ( 100 – 129 mg/dl in
patients with CHD) were randomized to Pravastatin 40 mg/dl or usual care . Mean follow
up for 4.8 years.
The results showed Pravastatin did not significantly reduce all cause mortality (
primary end point ) or coronary Heart disease events ( relative risk 0.91 p=0.16). Lack
of benefit is attributed to substantial ( 30 %) use of statins in the placebo group ,
resulting in a modest 17 % differential in total cholesterol between Pravastatin and
usual case groups.
PHYSICIAN HEALTH STUDY 92
It was a study that was conducted among the physicians to estimate the primary
prevention of coronary heart disease and malignancy by aspirin and placebo beta
carotene. It was conducted as a double blinded trial and also randomized and controlled
trail. Physicians of 40-84 years of age were included in the study. Then the individuals
who did not have coronary heart disease, ,malignancy , high blood pressure were taken
and the lipid profile of them were tested. They are the total cholesterol, high density
lipoprotein , non HDL and the ratio between the total cholesterol and high density
lipoprotein was calculated. Later on following these people over 14 years showed that
persons with high levels of these parameters developed hypertension whereas the persons
with low range of these parameters did not develop hypertension that significantly.
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Reduction in the risk of developing hypertension was seen in patients with higher
value of high density lipoprotein which was 32%. Thus this study conducted in healthy
physicians showed that lipid profile abnormalities lead to the development of high blood
pressure.
LIPID PROFILE IN HYPERTENSIVE NIGERIANS 93
Lipid profile studied in 150 hypertensive patients aged 30 – 59 and 30 years and
socio economic status matched normotensive controls using standard laboratory
techniques . Of the hypertensive patients 54% were females and 46% were
males.Hypertensive patients have significantly higher lipid profiles except for HDLc
which did not showed any difference in the two groups.
LIPID PROFILE OF HYPERTENSIVE PATIENTS IN SPAIN 94
In a Spanish hospital a study was conducted in people of mean age of forty five
years. The people were divided into two groups with 23 healthy people and 27 people
with high blood pressure. The body mass index of the patient were matched.the persons
were subjected to many analysis . Statistical analysis was done using the student’s t test
and Welch’s test. The values of triglycerides, uric acid, total cholesterol, creatinine and
chloride was higher in hypertensive people.
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LIPID PROFILE OF HYPERTENSIVE PATIENTS IN BANGLADESH 95
This prospective study carried out in department of bio chemistry and molecular
biology , university of Rajshahi , Bangaladesh. 60 human subjects of age ranging from
33 – 60 years were studied . Among these 40 were hypertensive and 20 were
normotensive . Their lipid profile results were collected and analyzed statistically. The
total cholesterol ( 241.25 vs 182.14 ) , triglycerides ( 184.77 vs 142.73 ) and LDL c (
154.32 vs 105.73 ) were significantly higher and HDL c ( 32.91 vs 42.88 ) was
significantly low among hypertensive patients.
MULTICENTRIC HYPERTENSIVE POPULATION STUDY IN UAE 96
Study conducted in 162 hypertensive and 112 normotensive matched
for age , gender , & ethnicity to determine ET-1 , NO, lipid profile. Levels of VLDL
and TG were significantly higher ( P < 0.01 ) in hypertensive. In contrast total
cholesterol ( P < 0.01 ) and LDL c ( P < 0.001 ) were lower among hypertensive. ET-
1 and NO were significantly higher in hypertensive.
MANAGEMENT OF HYPERTENSION IN METABOLIC SYNDROME
Main line of management in patients with hypertension and metabolic syndrome is
the lifestyle changes. The changes that are warranted are smoking cessation, quitting
alcohol, physical activity, reducing the body weight, change in diet including salt
restricted diet, calorie restricted diet. These non-pharmacological changes are alone not
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enough to maintain the normal level of blood pressure97,98.
Pharmacological therapy used to treat high blood pressure are selected in such a
way they also exert some effect on the other components of metabolic syndrome. Thus
the drugs that are chosen are the one which act on the rein angiotensin aldosterone
system, angiotensin convertase inhibitors, (ARBs) angiotensin receptor blockers, central
sympatholytic agents99,100.
Studies conducted on these drugs have shown that the drug of first choice is
generally the drugs acting on renin angiotensin system. These agents have inhibition on
sympathetic system and also increase the sensitivity to insulin98. Drugs like imidazoline
which belong to the class of central sympatholytic agents found to have many favourable
effects. The drug by inhibition of sympathetic outflow to the skeletal muscles produces
an increase in insulin sensitivity101.
Thus considering the various effects of hypertension in patients with metabolic
system , the hypertension is managed by targeting on many metabolic factors.
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MATERIALS AND METHODS
Patients newly detected as hypertensive in hypertensive clinic, medical out
patient department and ward of Government Vellore Medical College Hospital were
taken. Study period is from October 2015 to September 2016.
The study design is cross sectional study.
STUDY GROUP
The study included newly detected hypertensive patients of age group  31-75
years.
PATIENTS WHO WHERE EXCLUDED FROM STUDY
1. Patients who are already known hypertensives and on drugs
2. Patients with secondary hypertension
3. Newly diagnosed hypertensive patients with one or more complications like CVA,
CAD, renal, hepatic and other endocrine diseases
4. Patients with secondary cause of obesity
5. Hypertensive patients who are alcoholics
6. Patients on steroidal or other medications likely to cause elevated plasma glucose
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7. Any acute illness
8. Pregnant women
9. Patients not willing to participate in the study are excluded from the study
The participants were given clear and detailed information about the study. Then
informed consent was obtained from the participants. Following which the participants
were subjected to an interview and analysis for exclusion criteria. Patients who were
meeting the inclusion criteria and did not fit in any exclusion criteria were selected.
These selected patients participated in the study.
Totally 150 newly detected hypertensive patients were included in the study.
History regarding the patient’s smoking, alcohol consumption, occupation , daily
activities and hypertension in family members were asked in detail.
The patients socioeconomic status was assessed and classified according to
modified kuppuswamy scale (2007). Metabolic equivalent of task was used to classify the
patients as sedentary and non sedentary. Participants with daily physical activity of MET
of < 1.5 was considered to be sedentary as per WHO.
Participants who smoke more than or equal to 5 cigarettes per day were taken as
smokers.
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MEASUREMENTS
WAIST CIRCUMFERENCE
The waist circumference is measured midway between the costal margin and iliac
crest. And the measurement is taken after asking the patient to take two normal breaths
and at the end of second breath measurement of waist circumference is taken.
HIP CIRCUMFERENCE
Hip circumference is measured with tape parallel to the floor around the widest
portion of the buttocks, with the patient wearing little clothing.
Waist – hip ratio was calculated. Body mass index (BMI) was calculated by using
the formula,
BMI = body weight (kg) / [height]2 (metres)
OBESE
Participants with waist circumference for women ≥80 cm and men ≥90cm, waist
hip ratio for women ≥0.85 and men ≥0.90, and BMI of ≥ 25 kg / m2 were considered
obese.
Blood pressure was measured with patient in sitting posture and arm at the level
of heart. After 30 minutes of rest and in the right arm of the patient blood pressure was
measured. For preceding six hours the patient was abstained from caffeine intake and
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smoking. The blood pressure was again measured at least 24 hours later and average of
the two readings was taken.
BLOOD COLLECTION
After an overnight 12 hours of fasting, venous blood sample of five ml was
collected for the purpose of investigations.The method used to determine total
cholesterol (TC), triglycerides (TGL) and HDL c is enzyme calorimetric method.
Friedeward formula is used to calculate LDL-c and VLDL-c.
LDL-c = TC – ( HDL + VLDL )
Participants with total cholesterol value ≥ 200 or triglycerides value ≥ 150 or
LDL –c value ≥ 130 or HDL-c ≤ 40 were considered to have dyslipidemia.
Metabolic syndrome is said to be present , when 3 out of 5 criteria is present according to
modified NCEP ATP III.
The statistical analysis is done using SPSS16 software. A p value of <0.05 is taken
as significant. The influence of various factors on metabolic syndrome is studied. The
statistical significance is studied using chi-square test. ANOVA is used to analyze the
effect of multiple factors on metabolic syndrome. The mean values of lipid profile was
calculated and the significance of difference of mean was calculated by using unpaired
test.
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RESULTS AND ANALYSIS
The 150 newly detected hypertensive individuals are studied and analysed in
our study. There are 78 (52%) males and 72 (48%) females in our study.
GENDER DISTRIBUTION
GENDER NO OF PATIENTS
MALE 78
FEMALE 72
49
AGE DISTRIBUTION
The age distribution of our study population has more people belonging to
60-70 age group.
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SOCIO ECONOMIC STATUS DISTRIBUTION
SOCIOECONOMIC STATUS NO OF PATIENTS
UPPER MIDDLE 18
LOWER MIDDLE 46
UPPER LOWER 57
LOWER 29
The distribution of the study population in various socioeconomic classes
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according to modified kuppuswamy scale (2007) is 18 patients belong to (class 2) upper
middle class, 46 patients belong to lower middle class (class 3), 57 patients belong to
upper lower class (class 4) and 29 patients belong to lower class (class5). Most of the
patients belong to class 4.
LIFE STYLE DISTRIBUTION
LIFE STYLE NO OF PATIENTS
NON-SEDENTARY 60
SEDENTARY 90
The study population is divided into two groups as sedentary and non-sedentary
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people based on their daily physical activity. There are 90 patients belonging to sedentary
group and 60 patients belonging to non-sedentary group.
SMOKING DISTRIBUTION
SMOKING HABITS NO OF PATIENTS
SMOKERS MALE 28
NON SMOKERS MALE 50
The smokers and non-smokers in the study population comprises of 28 smokers and
50 non-smokers male.
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STAGE OF HYPERTENSION
STAGE NO OF PATIENTS
STAGE 1 44
STAGE 2 106
The hypertensive patients of our study population on grouping into stage 1 and
stage 2 according to JNC 7, there are 44 patients belonging to stage 1 and 106 patients
belonging to stage 2 of hypertension.
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IMPAIRED FASTING BLOOD SUGAR DISTRIBUTION
FBS NO OF PATIENTS
< 100 Mg% 118
> 100 Mg% 32
The impaired fasting blood glucose (>100mg/dl) is found to be present in 32
patients (21.33%) and fasting blood glucose is found to be normal (<100mg /dl) in
118 patients (78.66%).
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TGL DISTRIBUTION
TGL NO OF PATIENTS
< 150 Mg% 35
> 150 Mg% 115
Elevated triglycerides that is greater than 150mg/dl is seen in 115 (76.66%)
patients. Normal triglyceride is seen in 35 patients (23.33%).
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HDL DISTRIBUTION IN MALE PATIENTS
HDL NO OF PATIENTS
< 40 Mg% 34
> 40 Mg% 44
The number of patients with low high-density lipoprotein value <40mg/dl is 34
(43.58%). The number of patients with high-density lipoprotein value above 40mg/dl
is 44 (56.42%).
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HDL DISTRIBUTION IN FEMALE PATIENTS
HDL NO OF PATIENTS
< 50 Mg% 9
> 50 Mg% 63
The number of patients having high-density lipoprotein value < 50 mg/dl is 9
(12.5%). The number of patients having high-density lipoprotein value >50 mg/dl is
63(87.5%).
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WAIST CIRCUMFERENCE IN MALE PATIENTS
WAIST CIRCUMFERENCE NO OF PATIENTS
<90 cm 42
≥90 cm 36
The waist circumference of ≥90cm for male is seen in 36 patients (46.15%). The
waist circumference of newly detected hypertensive males in our study is 42 (53.85%).
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WAIST CIRCUMFERENCE IN FEMALE PATIENTS
WAIST CIRCUMFERENCE NO OF PATIENTS
<80 cm 20
≥80 cm 52
The number of patients with waist circumference <80 cm in female in newly
detected hypertensive in our study population is 20(27.78%). The number of patients
with waist circumference ≥80 cm is 52 (72.22%).
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PREVALENCE OF METABOLIC SYNDROME
The prevalence of metabolic syndrome studied in 150 newly detected
hypertensive individuals showed that 59.33% of newly detected hypertensive individuals
has metabolic syndrome.
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GENDER Vs METABOLIC SYNDROME
GENDER
NO METABOLIC
SYNDROME
METABOLIC
SYNDROME TOTAL
MALE 35 43 78
FEMALE 26 46 72
61 89 150
P VALUE=0.275
The number of patients with metabolic syndrome among male and female
hypertensive patients are 43 (55.12%)and 46 (63.88%) respectively. There is no
statistical significant difference in prevalence between male and female population.
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AGE Vs METABOLIC SYNDROME
AGE
NO METABOLIC
SYNDROME
METABOLIC
SYNDROME
TOTAL
<50 YRS 22 28 50
≥50 YRS 39 61 100
TOTAL 61 89 150
P VALUE=0.557
The prevalence of metabolic syndrome among age groups less than and more
than 50 are studied. There are 28(56%) people with metabolic syndrome in age
group less than 50 and 61 people (61%) in age group more than 50. There is no st
atistical significance in the prevalence in two age groups in our study.
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LIFE STYLE Vs METABOLIC SYNDROME
LIFE STYLE NO METABOLIC METABOLIC TOTAL
SYNDROME SYNDROME
NORMAL 30 30 60
SEDENTARY 31 59 90
61 89 150
P VALUE=0.05
The number of patients with metabolic syndrome in sedentary group is
65.55% and non-sedentary group is 50%. Thus a high prevalence of metabolic
syndrome is seen in people with sedentary lifestyle when compared to non-
sedentary people. The difference is statistically significant .
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SMOKING Vs METABOLIC SYNDROME
SMOKING NO METABOLIC METABOLIC TOTAL
SYNDROME SYNDROME
SMOKER MALE 6 22 28
NON SMOKER
29 21 50
MALE
TOTAL 35 43 78
P VALUE=0.001
The patients with metabolic syndrome among smokers and non-smoker
males are 22 (78.57%) and 21 (42%). The prevalence is high among smokers and
the difference is statistically significant.
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STAGE OF HYPERTENSION Vs METABOLIC SYNDROME
STAGE NO METABOLIC METABOLIC TOTAL
SYNDROME SYNDROME
STAGE 1 25 19 44
STAGE 2 36 70 106
TOTAL 61 89 150
P VALUE=0.009
The prevalence of metabolic syndrome among hypertensive patients divided
as stage 1 and stage 2 shows that 19 patients (43.18%) in stage 1 has metabolic
syndrome and 70 (66.02%) patients in stage 2 has metabolic syndrome. The
difference between the two is statistically significant.
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IMPACT OF VARIOUS FACTORS ON METABOLIC SYNDROME IN OUR
STUDY
FACTORS SIGNIFICANCE ( PVALUE )
HYPERTENSION STAGE 0.009
LIFE STYLE 0.058
SOCIO ECOMOMIC STATUS 0.921
SMOKING 0.931
The influence of various factors on the prevalence of metabolic syndrome in our
study is as follows. The stage of hypertension is the first most influential factor on
prevalence of metabolic syndrome. The other factors that influence the prevalence in
descending order are lifestyle, socioeconomic status and smoking.
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FREQUENCY OF INDIVIDUAL COMPONENTS IN METABOLIC SYNDROME IN
ALL INDIVIDUALS
COMPONENT MALE FEMALE
ELEVATED TGL 80.76% 73.61%
ABNORMAL WAIST 46.15% 72.22%
CIRCUMFERENCE
LOW HDL 43.58% 12.5%
IMPAIRED FASTING 26.92% 15.27%
BLOOD GLUCOSE
FREQUENCY OF EACH COMPONENTS IN ALL MALE AND FEMALE
The prevalence of each component of metabolic syndrome in male is found to be
elevated triglycerides (80.76%), abnormal waist circumference (46.15%) , low HDL
(43.58%), impaired fasting blood glucose (26.92%) and in females the same
component’s prevalence are 73.61%, 72.22%, 12.5%, 15.27% respectively.
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FREQUENCY OF EACH COMPONENTS IN PATIENTS WITH
METABOLIC SYNDROME
COMPONENTS MALE FEMALE
ELEVATED TGL 97.67% 93.47%
ABNORMAL WAIST 79.06% 89.13%
CIRCUMFERENCE
76.74% 97.8%
LOW HDL
IMPAIRED BLOOD 39.53% 17.39%
GLUCOSE
FREQUENCY OF EACH COMPONENT IN PATIENTS WITH METABOLIC
SYNDROME
The prevalence of each component in patients with metabolic syndrome in our
study shows that in male, elevated TGL (97.67%)is the most common component being
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seen. It is followed by abnormal waist circumference (79.06%), low HDL (76.74%),
impaired blood glucose (39.53%). Among females with metabolic syndrome the
prevalence of components are in the following order-low HDL (97.8%), elevated TGL
(93.47%), abnormal waist circumference (89.13%), impaired blood glucose (17.39%).
LIPID PROFILE ABNORMALITIES IN HYPERTENSIVE PATIENTS
LIPID PERCENTAGE
TC 43.33%
TGL 76.8%
LDL 28.66%
HDL 44.4%
The prevalence of lipid profile abnormalities in hypertensive patients is elevated
TC 43.33%, elevated TGL 76.8%, elevated LDL 28.66% and low HDL 44.4%.
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INFLUENCE OF AGE
AGE ELEVATED TC
<50 years 28%
≥50 years 50.4%
The prevalence of elevated TC in hypertensive patients belonging to age <50 years
is 28% and ≥50 years is 50.4%. The difference is statistically significant.
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INFLUENCE OF GENDER
GENDER HDL
MALE 43.58%
FEMALE 12.5%
p = 0.003
The prevalence of low HDL among male and female is 43.58% and 12.5%. The
difference between the two is statistically significant.
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INFLUENCE OF LIFESTYLE
LIPID (Mean value) SEDENTARY NON-SEDENTARY
TC 205.77 mg/dl 185.02 mg/dl
TGL 206.34mg/dl 178.42 mg/dl
LDL 125.83mg/dl 112.57 mg/dl
HDL 41.76 mg/dl 38.58 mg/dl
The mean values of lipid profile abnormalities are compared between sedentary
and non-sedentary hypertensive people. The difference between the means TC, TGL,
LDL, HDL between the two group is statistically significant with p value of 0.0001, 0.01,
0. 001,0.002 respectively.
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COMPARISON OF OBESITY AND LIPID
PROFILE BMI AND LIPID PROFILE
BM≥25 BMI<25 P VALUE
TC 204.58 184.06 <0.0001
HDL 40.96 39.6 0.2503
LDL 123.57 114.76 0.0484
TGL 205.63 175.41 0.0144
The comparison of lipid profile of people with BMI <25 and ≥25 shows that there is
significant difference in the values of total cholesterol, low density lipoprotein,
triglycerides. The values are high in people with BMI ≥25.
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WAIST CIRCUMFERENCE AND LIPID IN MALES
WC≥90 CM WC<90 CM P VALUE
TC 102.81 85.21 <0.0001
HDL 37.56 39.07 0.2709
LDL 126.52 111.51 0.0021
TGL 206.3 181.01 0.0641
Thus on comparison of lipid profile of males with waist circumference <90 cm
and ≥90 cm shows that the total cholesterol, low density lipoprotein, triglycerides are
significantly high in obese people.
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WAIST CIRCUMFERENCE AND LIPID IN FEMALE
WC≥80 CM WC<80 CM P VALUE
TC 204.89 193.52 0.01184
HDL 42.02 43.84 0.3054
LDL 120.32 127.4 0.3409
TGL 209.03 165.68 0.023
This shows that the female with waist circumference of ≥80 cm have significantly
higher values of total cholesterol and triglycerides.
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WAIST- HIP RATIO AND LIPID IN MALE
WHR≥0.90 WHR<0.90 P VALUE
TC 201.92 182 0.0007
HDL 38.17 39 0.558
LDL 123.61 110.16 0.0077
TGL 201.75 176.98 0.0656
The  lipid  profile  of  male  with  waist-hip  ratio  of ≥0.90  that  is
obese  group  have statistically  high  values  of  total  cholesterol,  low
density  lipoprotein,  triglycerides compared to male with <0.9 waist-hip
ratio.
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WAIST-HIP RATIO AND LIPID IN FEAMLE
WHR≥0.85 WHR<0.85 P VALUE
TC 200.69 201.6 0.9075
HDL 42.46 43.15 0.716
LDL 120.58 128.5 0.315
TGL 206.02 178.35 0.215
The lipid profile of female with waist-hip ratio <0.85 and ≥0.85 did
not show any statistical difference in the lipid values.
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CONTINUOUS VARIABLES STATISTICS
S.no FACTORS MEAN MEDIAN RANGE
1 AGE 55.6866 57.5 30-75
2 HEIGHT 156.6733 156.5 138-174
3 WEIGHT 66.54 65 48-97
4
BODY MASS
27.314 26.4086 19.8-40.42
INDEX
5
WAIST
91.64 89 72-116
CIRCUMFERENCE
6 WAIST-HIP RATIO 0.9021 0.8916 0.76-1.078
7
SYSTOLIC BLOOD
163.6266 162 130-200
PRESSURE
8 DIASTOLIC BP 95.5333 96 70-140
9 FBS 94.52 95 72-136
11 TC 197.4666 192 146-283
12 TG 195.156 180 58-495
13 LDL 120.522 117.5 64-195
14 HDL 40.486 41 24-56
15 VLDL 40.31 36.05 12-128
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DISCUSSION
PREVALENCE OF METABOLIC SYNDROME
The study population of 150 newly detected hypertensive individuals, there are
78 (52%) males and 72 (48%) females. The mean age of the study population is 55.68
years. There are 29 smokers (37.179%) out of 78 males. All the females are non-
smokers.
The prevalence of metabolic syndrome calculated according to NCEP ATP
III criteria is 59.33% that is 89 patients out of 150 newly detected hypertensive
people.
The prevalence of metabolic syndrome studied in newly detected hypertensive
people conducted by Anusha Govindula, Chandrasekhar Valupadas, Sabitha Panchagiri
at outpatient department of Mahatma Gandhi Memorial Hospital in Warangal,
Telangana, India, among 120 hypertensive patients (75 male; 45 female) with mean age
of 53.28 ± 12.98 years, according to NCEP ATP III, showed that 82.5% were falling in
this criterion.
Similar studies conducted in a tertiary care hospital in the northern hilly state of
Himachal Pradesh, India, by Surendhar Thakur et al102, showed that the prevalence
among 118 hypertensive patients were 68.6%.
Another cross-sectional study including 102 hypertensive outpatients at a teaching
hospital in Brazil , including patients >18 years of age, showed a prevalence of 71.6%
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according to NCEP ATP III criteria. The prevalence in western countries is because of
increasing central obesity among people.
Studies conducted across Europe by Farsang et al reported that highest
prevalence of metabolic syndrome from Central Europe and lowest from the
Mediterranean. Cohort studies conducted in Spain gave a report of 52% of prevalence
of metabolic syndrome.
Thus ranging from 50% to 68% the prevalence shows a wide range. Dietary
factors, genetics, lifestyles have been found be the cause for these variations in the
prevalence between countries.
INFLUENCE OF GENDER
The prevalence of metabolic syndrome among male were 55.13% and among
female were 68.6%. The prevalence among female is higher than that of male. In a study
conducted in West Ethiopia showed that the prevalence of metabolic syndrome in female
according to NCEP ATP III criteria is 46.5% higher when compared to male which is
31.3%. Female dominance was also seen in study conducted by Arkhangel in Russia,
Korea and China. The results are comparable to the study conducted in Pakistan and
similar to Frinks cohort study. The female dominance might be due to difference in the
cut-off points in metabolic syndrome criteria. An another important reason for increased
prevalence in females is due to increasing central obesity in women than men in both
developing and developed countries.
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INFLUENCE OF AGE
The newly detected hypertensive individual in our study were divided into two
groups as people < 50 years and >50 years of age. The prevalence of metabolic syndrome
in these age group on analysis showed that there is no significant difference in the
prevalence based on age group. Similarly study conducted by Apurva Sawant, Ranjit
Mankeshwar et al103 in Mumbai, India among 560 subjects showed there was no
significant difference in the prevalence of metabolic syndrome among different age
groups.
The results are similar to the study conducted in Nigeria by Adeseye A. Akintunde
et al, in cardiology unit of LAUTECH teaching hospital, which showed no statistical
significance in age wise distribution of metabolic syndrome.
INFLUENCE OF LIFESTYLE
The patients routine daily lifestyle was asked about and they were classified as
sedentary and non-sedentary lifestyle. In our study there are 60 people with non-
sedentary lifestyle and there are 90 people with sedentary lifestyle. The prevalence of
metabolic syndrome among sedentary group is 65.55%. The prevalence among non-
sedentary group is 50%. The difference between the two is statistically significant.
The study conducted by Antonio Cabrera de Leon, Maria del C. Rodriguez-Perez et
al showed that sedentary lifestyle is associated with increased prevalence of metabolic
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syndrome both by NCEP ATP III and IDF criteria. Lakka TA, Laaksonen DE et al
conducted study among 1069 males showed that sedentary lifestyle has association with
metabolic syndrome. The sedentary lifestyle was found to have direct relation with waist
and hip circumferences, body mass index, systolic blood pressure, triglycerides,
apolipoprotein B and inversely with high-density lipoprotein. So all these factors leads to
direct association with metabolic syndrome.
INFLUENCE OF SOCIOECONOMIC STATUS
The prevalence of metabolic syndrome belonging to various socioeconomic class
according to modified kuppuswamy scale(2007) was 43.8% among class 2&3 and 56.2%
among class 4&5. This shows high prevalence among people with low socioeconomic
status. Another study conducted in India also showed high prevalence among people with
low per capita income.
Studies conducted by Zhan Y, Yu J, Chen R et al in china and by Matthews
KA, Räikkönen K et al showed that prevalence of metabolic syndrome was high in
people with low socioeconomic status. This could probably attributed to the stress,
poor health conscious diet among people with low socioeconomic class.
INFLUENCE OF SMOKING
In our study the prevalence of metabolic syndrome among smoker male is 78.57%
and the prevalence among non-smoker male is 42%. The difference is statistically
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significant with p value of 0.0018. A study conducted by Sandra N Slagter, Jana V van
Vliet-Ostaptchouk et al showed that increased metabolic syndrome in smokers
independent of sex and body mass index. A similar study conducted by Sang Woo Oh,
Yeong Sook Yoon et al among 24,389 men and 35,078 women showed that current
smoking is associated with increased prevalence of metabolic syndrome. Relation
between smoking and different components of metabolic syndrome was studied. Guang-
Rong Wang1 , Li Li et al conducted a study in urban residents of China and found that
the metabolic syndrome had increased prevalence among smokers.
Smokers have abnormality in lipoprotein metabolism and endothelial function.
Smoking also affected the waist circumference. It is found to increase the levels of
triglycerides, lower high-density lipoprotein and increase high-density lipoprotein/ apo
A1 levels. It produces unfavourable changes in apo A1, apo B and lipoprotein particle
size.Smoking also increases the risk of cardiovascular disease.
INFLUENCE OF STAGE OF HYPERTENSION
The hypertensive people where grouped into two groups as stage I and stage II
based on JNC 7. The prevalence of metabolic syndrome in each stage has been studied.
In our study there are 43.18% of people with metabolic syndrome were in stage I
hypertension and 66.02% of people with metabolic syndrome were in stage II
hypertension.
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The prevalence of metabolic syndrome is high in people with stage II
hypertension and the difference is statistically significant. Studies have shown that
people with metabolic syndrome have high blood pressure. This is because of
multiple risk factors being present like obesity, dyslipidemia , impaired blood glucose
levels and genetic factors.
IMPACT OF VARIOUS FACTORS ON METABOLIC SYNDROME
The influence of factors like smoking, socioeconomic status, lifestyle and stage
of hypertension on prevalence of metabolic syndrome is analysed by using ANOVA.
The results showed that stage of hypertension has most influence, followed by lifestyle,
socioeconomic status and finally smoking. The least impact by smoking could probably
be explained by the predominat non-smoking female population in our study.
FREQUENCY OF ALL COMPONENTS OF METABOLIC SYNDROME IN
HYPERTENSIVE PATIENTS
In our study the frequency of each component of metabolic syndrome is studied in
all 150 newly detected hypertensive individuals. The analysis shows that the elevated
triglycerides are the most frequent abnormality of all the other components of metabolic
syndrome in both gender that is 80.76% in males and 73.61% in females. In females then
it is followed by abnormal waist circumference (72.22%), impaired fasting blood glucose
(15.27%), then low high density lipoprotein (12.5%). In males following elevated
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triglycerides, abnormal waist circumference (46.15%), it is low high density lipoprotein
(43.58%), then impaired fasting blood glucose (26.92%).
In a study conducted in Telengana by Anusha Govindula, Chandrasekhar
Valupadas et al showed that elevated triglycerides to the most common abnormality
among all 5 components according to NCEP ATP III criteria.It is followed by
abnormal waist circumference and low high-density lipoprotein.
FREQUENCY OF VARIOUS COMPONENTS OF METABOLIC SYNDROME
The frequency of various components of metabolic syndrome according to our study
is in the following order for men – elevated triglycerides (97.67%), abnormal waist
circumference (79.06%),low high-density lipoprotein (76.74%) impaired fasting blood
glucose (39.53%). Elevated triglycerides is the most frequent component of metabolic
syndrome found among men in our study.
The frequency of various components among female is in the following order,
low high-density lipoprotein (97.8%) , elevated triglycerides (93.47%), abnormal waist
circumference (89.13%) and impaired fasting blood glucose (17.39%). Low high-
density lipoprotein is the most frequent component among women.
Studies conducted by D.S.Prasad, Z.Kabir et al in SB Salagre, SM Itolikar
et al104 in eastern part of India showed that low high-density lipoprotein is the most
frequent component among female. Among male central obesity was the most common
component. The high fasting blood glucose was found to be the least frequent
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component. The results of our study is similar to this study conducted in our country.
SB Salagre, SM Itolikar et al conducted study in Mumbai which showed that
elevated trigycerides (35.14%)were the most frequent component found among men.
Our study also shows similar report. Fasting blood glucose (35.14%) was found to be
the most common component overall in the study.
Study conducted in Warangal, India showed that elevated triglycerides, waist
circumference, low high-density lipoprotein, elevated fasting blood glucose were the
descending order of frequency of components of metabolic syndrome.
PREVALENCE OF LIPID ANORMALITIES IN HYPERTENSIVE INDIVIDUALS
The prevalence of lipid profile abnormalities in our study is in the order of
elevated triglycerides (76.8%), low high-density lipoprotein (44.4%), elevated total
cholesterol (43.33%), high low-density lipoprotein ( 28.66%). The mean values of TC,
TGL, HDL, LDL in our study are 197.4mg/dl, 195.156 mg/dl, 40.486 mg/dl,
120.522mg/dl respectively.
INFLUENCE OF AGE
In our study the patients are divided into two groups age groups as less than
50years and more than 50 years. The prevalence of elevated total cholesterol among
less than 50 years is 28%. And among more than 50 years group is 50.4%. The
difference is statistically significant (p = 0.009).
The prevalence of elevated LDL is 30.69%, low HDL is 44.55%, LDL is
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30.69% among people more than 50 years. But the difference is not statistically
significant.
INFLUENCE OF GENDER
The difference in prevalence of dyslipidemia is studied between male and
female hypertensive patients. The prevalence of low HDL is statistically significant
between male and female with a p value of 0.003.
Studies conducted in Mumbai, Telangana also showed similar results of low HDL
among female.
INFLUENCE OF LIFESTYLE
The people in our study are divided into sedentary and non-sedentary. The
prevalence of lipid profile abnormalities among sedentary and non-sedentary people is
statistically significant by comparing the mean values. The mean values are TC
(205.77mg/dl and 185.02 mg/dl), TGL (206.34mg/dl and 178.42 mg/dl), LDL
(125.83mg/dl and 112.57mg/dl) and HDL (41.76 mg/dl and 38.58mg/dl). In Brazil,
similar study conducted by Ignez Salas Martius et al showed results with similar lipid
profile abnormalities.
INFUENCE BY OBESITY
BASED ON BMI
The comparison of lipid profile of people with BMI <25 and ≥25 shows that
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there is significant difference in the values of total cholesterol, low density
lipoprotein, triglycerides. The values are high in people with BMI ≥25.The results are
similar to the study conducted by S .A.Desai et al105 with lipid profile values higher
in obese patients.
BASED ON WAIST CIRCUMFERENCE
On comparison of lipid profile of males with waist circumference <90 cm and
≥90 cm shows that the total cholesterol, low density lipoprotein, triglycerides are
significantly high in obese people. The study also shows that the female with waist
circumference of ≥80 cm have significantly higher values of total cholesterol and
triglycerides.
BASED ON WAIST-HIP RATIO
The lipid profile of male with waist-hip ratio of ≥0.90 that is obese group have
statistically high values of total cholesterol, low density lipoprotein, triglycerides compared
to male with <0.9 waist-hip ratio. The lipid profile of female with waist-hip ratio <0.85 and
≥0.85 did not show any statistical difference in the lipid values.
By all the methods, it is shown that the obesity is related to lipid profile
abnormalities.
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CONCLUSION
1. The prevalence of metabolic syndrome is 59.33% and it is more in females
compared to males.
2. The smoking habit, lifestyle, stage of hypertension have significant effect on
prevalence of metabolic syndrome.
3. Among the components of metabolic syndrome in hypertensive males and
females, elevated TGL is most common.
4. Among the components of metabolic syndrome in hypertensive males
with metabolic syndrome , elevated TGL is most common.
5. Among the components of metabolic syndrome in hypertensive females
with metabolic syndrome , low HDL is most common.
6. The elevated TC in hypertensive patients is significantly higher in age group ≥ 50
years .
7. The low HDL shows significant difference between male and female.
8. The dyslipidemia shows significant difference between people with sedentary
and non-sedentary lifestyle.
9. There is a significant difference in the lipid profile values of obese
people compared to non-obese individuals.
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 METABOLIC SYNDROME IN NEWLY DETECTED HYPERTENSIVE 
INDIVIDUALS 
PROFOMA 
 
    
No:         OP No: 
Name:         Age:   Sex: 
Address:                  Phone No: 
 
Socio-Economic status: (by modified Kuppuswamy scale) 
 
Class I II III IV V 
 
Life style: (physical activity < 1.5 MET hour / day) 
 
Sedentary Non Sedentary 
 
H/O smoking: (> 5 cigarettes / day) 
 
Yes No 
 
 
    H/O Hypertension: 
 
Yes No 
 
    Anthropometry 
 
Height (in cm) Weight (in kg) BMI 
Waist (in cm) Hip ( in cm) WHR 
 
 
 
 
 
 
 
 
 
  
 Blood Pressure 
 
            Sitting R UL 
 
L UL 
            Supine   
 
Investigations      Lipid profile 
Blood Sugar       TC - 
Fasting -       HDL - 
                          LDL - 
     B. Urea     -                                                         VLDL-    
TG  - 
S. Creatinine -                                                          
       
 
Modified (2007) Kuppuswamy socioeconomic status scale 
 
EDUCATION                                           OCCUPATION 
 
Profession / Honors 7   Profession 10  
Graduate / PG 6   Semi – profession 6  
Post high school / 
diploma 
5   Clerical / shop owner/ 
farmer 
5  
High school certificate 4   Skilled worker 4  
Mid school certificate 3   Semi-skilled worker 3  
Primary certificate 2   Unskilled worker 2  
Illiterate 1   Unemployed 1  
 
 
Family income / month 
 
>  19575 12   Total 
Points 
  Class 
9788- 19574 10    26 - 29 Upper – I 
7323 – 9787 6    16 - 25 Upper middle - II 
4894 – 7322 4    11 - 15 Lower middle - III 
2936 – 4893 3      5 - 10 Upper lower – IV 
980 – 2935  2   < 5  Lower V 
< 980 1   Patients  points  class  
 
  
Physical activity assessment 
 
Activity MET Duration MET 
calculation 
Washing / Housekeeping/ driving / 
cooking 
1-2   
Carpentry / walking (4mph) / Dancing 3-5   
Digging in garden / Tennis games / 
swimming / cycling 10mph 
5-7   
Tracking / jogging 7-9   
Carrying loads / walking uphill / 
running 
>9   
Total MET    
 
Life Style 
 
Sedentary Non – sedentary 
 
 
 
 
 
 
 
 
 
  
 MASTER CHART 
  
 
 
 
 
 
 
 
 
  
   
   
   
 KEY TO MASTER CHART 
SL.NO – Serial number 
SES – Socio Economic Status 
LS- Life Style 
BMI – Body Mass Index 
WHR – Waist Hip Ratio 
SBP – Systolic Blood Pressure 
DBP – Diastolic Blood Pressure 
FBS – Fasting Blood Sugar 
TC – Total Cholesterol 
HDL – High Density Lipoprotein 
LDL – Low Density Lipoprotein 
VLDL – Very Low Density Lipoprotein 
TG - Triglyceride 
MS – Metabolic Syndrome 
 
 
 
 
 
 
 
    
 TeúLtTYoLÞdÏ Bn®u ®YWm 
Bn®u úSôdLm 
1) ×§RôL LiP±VlThP EVo CWjR AÝjR R² SToL°p Cp Y[o£ûR Uôt\ úSôndÏ± úSônjRôdLm 
T¥dL, 
2) EVo CWjR AÝjR R²SToLs ùLôÝl©p ÑV®YW ùRôPoTô] úLô[ôßLÞm úSônjRôdLØm 
Øû\T¥dL, 
3) EVo CWjR AÝjR R²SToLs ùLôÝl©p ÑV®YWj§p. úSôn UdLh§Ws Utßm NêL LôW¦Ls 
T¥dL, 
 
Bn®p TeúLtTRtLô] RÏ§Ls : 
 31 – 75 YVÕ ùLôiP ×§RôL LiÓ©¥dLlThP EVo CWjR AÝjR R²SToLs, 
ùNnØû\ ®[dLm  
 CkR Bn®p TeúLtTYoLÞdÏ ØÝ EPp T¬úNôRû] ùNnÕ úSô«u A±Ï±Ls LiP±VlTÓm, 
 EPp T¬UôQeLs Utßm CWjR AÝjR A[ÅÓLs GÓdLlTÓ¡u\], 
 CWjR NodLûW Utßm ùLôÝl×Lô] CWjR T¬úNôRû] ùNnVlTÓm, 
 EPt T¬úNôRû]«]ôp GkR TdL ®û[ÜLÞm úSWôÕ, CWjRl T¬úNôRû]«]ôp £ß Y­ Utßm 
CWjRdL£Ü úS¬PXôm, CR]ôp Gq®R Tô§l×m HtTPôÕ, 
Hu TeúLtL úYiÓm  
 Y[o£ûR Uôt\ úSôndÏ± Es[Rô GuTûR LiP±YRtLôL, 
BWônf£ ¨ûXVm 
 ùTôÕ UÚjÕY Õû\. AWÑ úYío UÚjÕY Lpí¬ Utßm UÚjÕYUû]. úYío, 
  
  
 
